457 related articles for article (PubMed ID: 6196852)
1. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
3. Controlled multicenter pilot study of urokinase- heparin and streptokinase in deep vein thrombosis.
van de Loo JC; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Asbeck F; Marbet GA; Schmitt HE; Sewell AF; Duckert F
Thromb Haemost; 1983 Oct; 50(3):660-3. PubMed ID: 6359570
[TBL] [Abstract][Full Text] [Related]
4. Studies on the medical treatment of deep vein thrombosis.
Schulman S
Acta Med Scand Suppl; 1985; 704():1-68. PubMed ID: 3913282
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic treatment by infusion of streptokinase-plasminogen-complex (activator): laboratory effects.
Martin H; Auel H; Riedel C
Behring Inst Mitt; 1986 Feb; (79):263-71. PubMed ID: 2424424
[TBL] [Abstract][Full Text] [Related]
6. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].
Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K
Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345
[TBL] [Abstract][Full Text] [Related]
7. [Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction].
Goto S; Kawai Y; Watanabe K; Hori S; Abe S; Handa S; Ikeda Y
Kokyu To Junkan; 1992 Jan; 40(1):89-95. PubMed ID: 1532665
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator.
Zimmerman R; Gürsoy A; Horn A; Harenberg J; Diehm C; Kübler W
Semin Thromb Hemost; 1991 Jan; 17(1):48-54. PubMed ID: 1904629
[TBL] [Abstract][Full Text] [Related]
9. [Fibrinolytic therapy in deep venous thrombosis of the upper and lower extremity].
Kriessmann A; Theiss W; Lutilsky L; Wirtzfeld A; Seifert W; Grünberg G
Fortschr Med; 1977 Apr; 95(13):858-66. PubMed ID: 844772
[TBL] [Abstract][Full Text] [Related]
10. Intermittent plasminogen-streptokinase treatment of deep vein thrombosis.
Scully MF; Lane DA; Sagar S; Thomas DP; Kakkar VV
Thromb Haemost; 1977 Feb; 37(1):162-9. PubMed ID: 138963
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis--a review.
Kane KK
Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
[TBL] [Abstract][Full Text] [Related]
12. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
Van de Werf F; Ludbrook PA; Bergmann SR; Tiefenbrunn AJ; Fox KA; de Geest H; Verstraete M; Collen D; Sobel BE
N Engl J Med; 1984 Mar; 310(10):609-13. PubMed ID: 6537987
[TBL] [Abstract][Full Text] [Related]
13. [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method].
Ogloblina OG; Saburova OS; Semenova OA; Belova LA
Biokhimiia; 1994 Jan; 59(1):62-8. PubMed ID: 7509643
[TBL] [Abstract][Full Text] [Related]
14. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis.
Dupe RJ; English PD; Smith RA; Green J
Thromb Haemost; 1981 Aug; 46(2):528-34. PubMed ID: 6458112
[TBL] [Abstract][Full Text] [Related]
16. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Henkin J
Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
[TBL] [Abstract][Full Text] [Related]
17. Outcome of treatment of deep-vein thrombosis with urokinase: relationship to dosage, duration of therapy, age of the thrombus and laboratory changes.
D'Angelo A; Mannucci PM
Thromb Haemost; 1984 Apr; 51(2):236-9. PubMed ID: 6740556
[TBL] [Abstract][Full Text] [Related]
18. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
Collen D; Stassen JM; Verstraete M
J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
[TBL] [Abstract][Full Text] [Related]
19. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
Collatos C; Barton MH; Prasse KW; Moore JN
J Am Vet Med Assoc; 1995 Aug; 207(4):465-70. PubMed ID: 7591947
[TBL] [Abstract][Full Text] [Related]
20. [Fibrinolytic therapy of deep venous thrombosis. Streptokinase, urokinase, plasminogen substitution].
Theiss W; Kriessmann A; Wirtzfeld A
Dtsch Med Wochenschr; 1980 Feb; 105(8):243-6. PubMed ID: 6986252
[No Abstract] [Full Text] [Related]
[Next] [New Search]
